[46] A total of 18 out of 33 patients (55%) experienced a decline in PSA of more than 50%, resulting in a recommended Phase II abiraterone acetate dose of 1000 mg. KC-naive patients exhibited a ...

The recommended Phase II dose of abiraterone acetate is 1000 mg orally daily in combination with prednisone 5 mg twice daily. Side effects are minimal and mostly associated with secondary ...

Abiraterone acetate is currently given for two indications: Newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with prednisone 5 mg daily. For metastatic ...

All eligible patients received salvage radiotherapy plus 6 months of a GnRH agonist and randomization was to concurrent bicalutamide 50 mg or abiraterone acetate/prednisone 1000 mg/5 mg +apalutamide ...